Phase 1, Multicenter, Open-Label, Multiple-Dose Study of DS-8201a to Assess the Effect on the QT Interval, and Pharmacokinetics in Subjects with HER2-Expressing Metastatic and/or Unresectable Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2018
At a glance
- Drugs DS 8201 (Primary)
- Indications Advanced breast cancer
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 15 Jan 2018 Planned End Date changed from 1 Apr 2019 to 30 Sep 2018.
- 15 Jan 2018 Status changed from not yet recruiting to recruiting.
- 01 Dec 2017 New trial record